News

The SOLO-3 late-stage trial, which evaluated the efficacy and safety of Lynparza, featured 266 patients whose ovarian cancer relapsed following two or more lines of treatment. Patients were

Under the terms of the agreement, Agenus will receive $150m upon closing, which includes a $120m upfront cash payment and a $30m equity investment. The agreement also includes

The new facility, which is strategically located in close vicinity to the Ljubljana Airport, will carry out the distribution of finished products worldwide and will be used for

Under the collaboration, Gilead has exclusive options to license worldwide rights to product candidates that emerge from three Scholar Rock TGFβ programs: inhibitors that target activation of latent

UPSA is a French pharmaceutical manufacturer, which develops and produces pharmaceutical drugs and supplements for everyday ailments. The company provides various products in therapeutic areas, including pain, cough

According to Pfizer, the combination of the consumer healthcare businesses had registered global sales of nearly $12.7bn in 2017. GSK said that the combination will comprise two portfolios

Under the terms of the agreement, Innovare will use DelSiTech’s technology on its peptide membrane fusion inhibitor, targeting the envelope protein of human immunodeficiency virus-1 (HIV-1). DelSiTech is

Roxadustat is a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) indicated to treat patients who use hemodialysis or peritoneal dialysis. It will help induce coordinated erythropoiesis, increase red blood

MP0310 is a preclinical molecule designed to locally activate immune cells in the tumor by binding to FAP on tumor stromal cells (localizer) and co-stimulating T cells via